Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05626478
Other study ID # AVC-003
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 1, 2023
Est. completion date June 1, 2024

Study information

Verified date July 2023
Source Advanced Vision Care
Contact Nicole R Fram, M.D.
Phone 310-229-1220
Email nicfram@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery


Description:

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt Treating Pain, and inflamMation Following Cataract Surgery Compared to Topical Prednisolone Acetate 1%.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with clinically significant cataract and are planning to undergo non-complicated Clear Cornea Incision Cataract Extraction with Posterior Capsule IntraOcular Lens in one or both eyes - Are willing and able to comply with clinic visits and study related procedures - Are willing and able to sign the informed consent form Exclusion Criteria: - Under the age of 18 at the time of signing the Informed Consent Form - Pregnant or planning to become pregnant during the trial period - Have visual acuity potential of less than 20/30 as recorded by a Retinal Acuity Meter or Potential Acuity Meter glare testing - Have active infectious systemic disease - Have active infectious ocular or extraocular disease - Have punctal plug in the study eye - Have obstructed nasolacrimal duct in the study eye(s) (dacryocystitus) - Have known hypersensitivity to dexamethasone or are a known steroid responder - Have a history of ocular inflammation or macular edema - Has history of Laser Vision Correction (LASIK, PhotoRefractive Keratectomy) in the operated eye - Are currently being treated with immunomodulating agents in the study eye - Are currently being treated with immunosuppressants and/or oral steroids - Are currently being treated with corticosteroid implant (i.e Ozurdex) - Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye - Have a history of complete punctal occlusion in one or both punctum - Currently using topical ophthalmic steroid medications - Are unwilling or unable to comply with the study protocol - Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment

Study Design


Intervention

Drug:
Dextenza 0.4Mg Ophthalmic Insert
DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
Prednisolone Acetate 1% Oph Susp
Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
Prolensa 0.07% Ophthalmic Solution
Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.

Locations

Country Name City State
United States Advanced Vision Care Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Nicole Fram M.D.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Greenwood MD, Gorham RA, Boever KR. A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK). Clin Ophthalmol. 2020 Aug 6;14:2223-2228. doi: 10.2147/OPTH.S265311. eCollection 2020. — View Citation

Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum In: J Cataract Refract Surg. 2019 Jun;45(6):895. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Safety endpoint: corneal or retinal edema Measured by slit lamp examination and supporting imaging and testing such as Pachymetry measured in micrometer (µm) or Macular (Optical Coherence Tomography) Assessed throughout 90-day study period
Other Safety endpoint: Signs of Rebound Iritis Measured by slit lamp examination and scored by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1, (0-4 score scale) higher scores (4) mean a worse outcome. (specifically sub-grouped Blue vs. Brown eyed subjects) Assessed throughout 90-day study period
Other Safety endpoint: Change in IOP (IntraOcular Pressure) initiating rescue medications Measured by Applanation in millimeter Hg(Mercury), higher then 22mm Hg or lower then 10mm Hg mean a worse outcome and a need for rescue. Assessed throughout 90-day study period
Primary Mean change in anterior chamber inflammation (Cell and Flare) scores Measured by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1. 0-4 score scale, higher scores (4) mean a worse outcome. Assessed on Days 1,7,30,90
Primary Mean change in pain score Measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worst pain possible Assessed on Day 1,7, 30 and 90
Secondary Visual outcome (Best Corrected Visual Acuity) Measured by ETDRS (Early Treatment Diabetic Retinopathy Study) chart. 0-70 letter read score. higher scores mean a better outcome. Assessed on Day 1,7, 30 and 90
Secondary Absence of CME (Cystoid Macular Edema) Measured by OCT (Optical Coherence Tomography) Assessed on Day 90
Secondary Mean change in corneal staining measured by the National Eye Institute 0-4 score scale, higher scores (4) mean a worse outcome. Assessed on Day 7, 30 and 90
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05139771 - EndoArt® Implantation in Subjects With Chronic Corneal Edema N/A
Enrolling by invitation NCT05956535 - Air Optix® Night and Day® Aqua Therapeutic Wear
Completed NCT02332109 - ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy N/A
Completed NCT04498169 - A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy Phase 2
Active, not recruiting NCT06041256 - A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) Phase 1/Phase 2
Completed NCT04521140 - Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery Phase 4
Completed NCT05136443 - Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection Phase 4
Completed NCT01998568 - The Intraocular Pressure Measured by Different Tonometers in Corneal Edema N/A
Recruiting NCT04191629 - Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema Phase 1
Completed NCT04975971 - A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
Completed NCT05309135 - A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction Phase 1
Completed NCT01853696 - Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty Phase 4
Completed NCT01244334 - Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery. Phase 4
Completed NCT05891106 - AONDA Therapeutic Indication Study I
Active, not recruiting NCT04894110 - Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema Phase 1
Completed NCT01387620 - Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2% Phase 4
Completed NCT00346138 - A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema N/A
Completed NCT05271058 - Effect of Intracameral Steroids During Phacoemulsification on the Cornea Phase 3
Completed NCT01890252 - Hyper-CL™ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema N/A
Not yet recruiting NCT00800423 - Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema Phase 3